NASDAQ:HOLX - Hologic Stock Price, News, & Analysis

Get Started

$46.29 +1.06 (+2.34 %)

(As of 02/19/2019 07:32 AM ET)

Previous Close$45.23

Today's Range$45.14 - $46.32

52-Week Range$35.10 - $46.32

Volume2.00 million shs

Average Volume2.20 million shs

Market Capitalization$13.48 billion

P/E Ratio20.76

Dividend YieldN/A

Beta0.73

Hologic, Inc., a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. The company offers Aptima molecular diagnostic assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. It also provides breast imaging and analytics products, such as 2D and 3D mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, and breast biopsy and biopsy site markers, as well as localization, specimen radiology, ultrasound, and connectivity solutions. In addition, the company offers Selenia Dimensions and 3Dimensions gantries for performing 2D and tomosynthesis image acquisition and display; C-View and Intelligent 2D software products; SecurView Workstations; computer aided detection systems; and stereotactic breast biopsy systems. Further, it provides SculpSure, PicoSure, and MonaLisa Touch aesthetic treatment systems; TempSure, a radio frequency energy sourced platform; and MedLite and other products, and system components for medical aesthetics. Additionally, the company offers NovaSure, an endometrial ablation system to treat women suffering from abnormal uterine bleeding; MyoSure surgical products for removal of fibroids, and uterine polyps and other pathology; and Horizon DXA System and Fluoroscan Insight FD skeletal health products. It sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. The company was founded in 1985 and is headquartered in Marlborough, Massachusetts.

Receive HOLX News and Ratings via Email

Sign-up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry X-ray apparatus & tubes

Sub-IndustryHealth Care Equipment

SectorMedical

Current SymbolNASDAQ:HOLX

Previous Symbol

CUSIP43644010

Webwww.hologic.com

Phone508-263-2900

Debt

Debt-to-Equity Ratio1.18

Current Ratio1.30

Quick Ratio0.91

Price-To-Earnings

Trailing P/E Ratio20.76

Forward P/E Ratio19.21

P/E Growth2.11

Sales & Book Value

Annual Sales$3.22 billion

Price / Sales4.19

Cash Flow$4.1628 per share

Price / Cash Flow11.12

Book Value$8.22 per share

Price / Book5.63

Profitability

EPS (Most Recent Fiscal Year)$2.23

Net Income$-111,300,000.00

Net Margins-12.88%

Return on Equity25.59%

Return on Assets8.73%

Miscellaneous

Employees6,252

Outstanding Shares291,315,000

Market Cap$13.48 billion

OptionableOptionable

Hologic (NASDAQ:HOLX) Frequently Asked Questions

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) posted its quarterly earnings data on Wednesday, January, 30th. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.57 by $0.01. The medical equipment provider had revenue of $830.70 million for the quarter, compared to analysts' expectations of $823.22 million. Hologic had a positive return on equity of 25.59% and a negative net margin of 12.88%. Hologic's revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.55 EPS. View Hologic's Earnings History.

When is Hologic's next earnings date?

Hologic is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for Hologic.

What guidance has Hologic issued on next quarter's earnings?

Hologic updated its FY19 earnings guidance on Wednesday, January, 30th. The company provided earnings per share guidance of $2.39-2.43 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.41. The company issued revenue guidance of $3.31-3.34 billion, compared to the consensus revenue estimate of $3.33 billion.Hologic also updated its FY 2019 guidance to $2.39-2.43 EPS.

What price target have analysts set for HOLX?

15 equities research analysts have issued 12-month price objectives for Hologic's stock. Their forecasts range from $38.28 to $50.00. On average, they expect Hologic's share price to reach $43.9520 in the next twelve months. This suggests that the stock has a possible downside of 5.1%. View Analyst Price Targets for Hologic.

What is the consensus analysts' recommendation for Hologic?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 1 sell rating, 9 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Hologic.

What are Wall Street analysts saying about Hologic stock?

Here are some recent quotes from research analysts about Hologic stock:

1. According to Zacks Investment Research, "Hologic exited the first quarter of fiscal 2019 on a solid note led by double-digit constant currency growth in core businesses like U.S. Breast Health, International and Global Molecular Diagnostics. We are also upbeat about the recent product launches like the Omni hysteroscope and Panther Fusion Open Access functionality in the United States, the Panther Fusion Bordetella assay in Europe, and the Surgical hand piece for the TempSure radiofrequency system in North America. Backed by a portfolio of differentiated products, the company’s Breast Health business has been going strong. Hologic has outperformed its industry in the past three months. However, rising costs continue to exert pressure on adjusted operating margin. Also, company operating in a highly competitive landscape is a concern." (2/4/2019)
2. BTIG Research analysts commented, "Hologic preannounced F1Q revenue earlier this month, so focus around the formal report was on expectations for F2Q and FY19. In our view, guidance was set at an achievable level, with management pointing to concerns around anticipated negative foreign exchange impacts. Commentary underscored the recovery in the Breast Health segment and opportunities for upgrades in that business. We sensed a continued shift away from worries about the Cynosure Medical Aesthetics division and an emphasis on the solid results from the Core business (Breast and Diagnostics). It seems to us that the drivers increasing Breast and Diagnostics growth are multifactorial and sustainable, boosting our confidence that HOLX can continue to regain credibility and enjoy improved investor sentiment." (1/31/2019)
3. Needham & Company LLC analysts commented, "FDA’s latest monthly Act (MQSA) statistics were published on 1/7/19. The number of digital breast tomosynthesis (DBT) units increased by 66 during December which represents a 3% Y/ Y decrease. DBT unit penetration increased to 34.9% from 34.7% last month and facility penetration increased to 56.8% from 56.3% last month. More importantly, DBT units placements were down 2.5% in 4Q18 vs. 4Q17. HOLX’s Breast Imaging growth slowed slightly in January data seems to indicate that growth could slow more in F1Q19. We note however that HOLX preannounced F1Q19 results last week which included strong Breast Health performance. We note that HOLX’s 3D mammography sales are less than 13% of its total sales. Please contact your Needham salesperson for a copy of our MQSA data." (1/14/2019)
4. Canaccord Genuity analysts commented, "We believe the stock is up today because HOLX (1) removed uncertainty regarding its 2019 guide and (2) announced agreements to renew with LH and DGX, which we think alleviates a modest overhang on the stock. HOLX’s top line guide of ~2-3.5% growth is not enough for us to get excited about. We look for signs of faster growth and progress mitigating margin drags and reiterate our HOLD. We raise our PT from $41 to $43, as we roll forward a 16.5x multiple on our new ’20E Adj. EPS of $2.60. Alleviates lab contract overhang. HOLX has agreed to deals with large lab customers (LH & DGX), a positive outcome to a modest overhang on the stock. One deal is a multi- year" extension of its supply contract while the other provides instruments and tests. While we view these deals favorably, we believe HOLX likely made price concessions to do the deals." (11/8/2018)

Has Hologic been receiving favorable news coverage?

Media stories about HOLX stock have been trending very positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Hologic earned a news impact score of 3.3 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.

Who are some of Hologic's key competitors?

Some companies that are related to Hologic include Express Scripts (ESRX), HCA Healthcare (HCA), Vertex Pharmaceuticals (VRTX), Allergan (AGN), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Illumina (ILMN), Shire (SHP), Humana (HUM), Baxter International (BAX), Edwards Lifesciences (EW), Takeda Pharmaceutical (TKPYY), Actelion (ALIOF), FRESENIUS SE &/S (FSNUY) and ASTELLAS PHARMA/ADR (ALPMY).

Who are Hologic's key executives?

Hologic's management team includes the folowing people:

Mr. Stephen P. MacMillan, Chairman, CEO & Pres (Age 55)
Ms. Karleen M. Oberton, Chief Financial Officer (Age 49)
Mr. John M. Griffin, Gen. Counsel (Age 58)
Mr. Peter J. Valenti III, Division Pres of Breast & Skeletal Health Solutions (Age 56)
Mr. Thomas A. West, Division Pres of Diagnostics Solutions (Age 55)

Who are Hologic's major shareholders?

Hologic's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.42%), Parnassus Investments CA (5.33%), Geode Capital Management LLC (1.31%), Northern Trust Corp (1.10%), Dimensional Fund Advisors LP (0.74%) and Amundi Pioneer Asset Management Inc. (0.69%). Company insiders that own Hologic stock include Allison P Bebo, Benjamin Jordan Cohn, Charles J Dockendorff, Christiana Stamoulis, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Namal Nawana, Peter J Valenti III and Sally Crawford. View Institutional Ownership Trends for Hologic.

Which major investors are selling Hologic stock?

HOLX stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Parnassus Investments CA, American Capital Management Inc., Two Sigma Advisers LP, Bellevue Group AG, Trillium Asset Management LLC, First Trust Advisors LP and Bank of New York Mellon Corp. Company insiders that have sold Hologic company stock in the last year include Allison P Bebo, Benjamin Jordan Cohn, Christiana Stamoulis, Karleen Marie Oberton, Peter J Valenti III and Sally Crawford. View Insider Buying and Selling for Hologic.

Which major investors are buying Hologic stock?

HOLX stock was acquired by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, State of Tennessee Treasury Department, Vaughan Nelson Investment Management L.P., Los Angeles Capital Management & Equity Research Inc., Bank of America Corp DE, Geode Capital Management LLC, Korea Investment CORP and Legal & General Group Plc. Company insiders that have bought Hologic stock in the last two years include Charles J Dockendorff and Namal Nawana. View Insider Buying and Selling for Hologic.

How do I buy shares of Hologic?

Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hologic's stock price today?

One share of HOLX stock can currently be purchased for approximately $46.29.

How big of a company is Hologic?

Hologic has a market capitalization of $13.48 billion and generates $3.22 billion in revenue each year. The medical equipment provider earns $-111,300,000.00 in net income (profit) each year or $2.23 on an earnings per share basis. Hologic employs 6,252 workers across the globe.

What is Hologic's official website?

The official website for Hologic is http://www.hologic.com.

How can I contact Hologic?

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected]

MarketBeat Community Rating for Hologic (NASDAQ HOLX)

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		660 (Vote Outperform)
Underperform Votes:		487 (Vote Underperform)
Total Votes:		1,147

MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote "Outperform" if you believe HOLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOLX will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 2/19/2019 by MarketBeat.com Staff